AZ-LIMELIGHT-NETWORKS
23.6.2020 13:02:07 CEST | Business Wire | Press release
The COVID-19 pandemic is impacting lives across the globe, forcing people to change how they work, learn, access information, connect with one another and their entertainment options. Streaming is at the forefront of this new normal with global consumers now engaging with online video for an average of four hours and three minutes every day. That is according to a new global “How Video is Changing the World” report from Limelight Networks , Inc., (Nasdaq: LLNW), which exposes the new ways online video supports our daily activities during and after the pandemic.
As people quarantine in their homes, online video is enabling new forms of interactive entertainment to pass the time. With traditional sports leagues on hold, nearly one third (31 percent) of global consumers have had their first esports experience during the pandemic. With other live events cancelled, almost half (44 percent) of global consumers attended their first virtual concert. Exercising is also going virtual as athletic facilities remain closed. In fact, 31 percent have participated in an online fitness class and another 24 percent plan to in the next six months.
Additional insights from the report include:
- Online video fills the void of in-person social interactions. Globally, nine in ten (89 percent) people now use video chat to feel more connected, up from 61 percent prior to COVID-19.
- Consumers are using online video to access critical information. Most people (70 percent) have used online video to stay informed by watching live stream speeches and press conferences during the pandemic – 44 percent live streamed on news sites and 26 percent live streamed on social media. Even Baby Boomers (63 percent) tune into live streamed news and information online.
- Remote work and professional development rely on online video. As the pandemic has forced consumers to work remotely, 79 percent of people agree that online video equips them to maintain daily activities. One third (33 percent) of global consumers are working from home for the first time and say online video helps them stay connected to colleagues (24 percent) and work more efficiently (36 percent). More than half (58 percent) have or plan to use online video for professional development or to learn a new skill. Most people (83 percent) believe video-based learning will continue in the post-COVID world.
- The pandemic has sparked a rapid increase in telehealth across the globe. More than one fifth (22 percent) of people have recently met with their doctor virtually. This trend is expected to last beyond the pandemic with another quarter (27 percent) of global respondents planning to hold telehealth appointments in the next six months. Telehealth usage is highest for India where 81 percent of consumers have met or plan to meet with their doctor virtually.
“The pandemic has pushed the bounds of online video. Applications such as remote collaboration, e-learning and telehealth, have been widely available for some time now; but today, they’re essential to continuing life in quarantine,” said Mike Milligan, senior director of product and solution marketing at Limelight Networks. “Many people turned to online video to connect with others and maintain daily activities during the pandemic, but it won't stop once quarantine is over. Our report emphasizes that online video will remain an important part of our lives in the new normal.”
The “How Video is Changing the World” report is based on responses from 5,000 consumers ages 18 and older in France, Germany, India, Italy, Japan, Scandinavia, Singapore, South Korea, the United Kingdom, and the United States who watch one hour or more of online video each day. The full report is available here .
About Limelight Networks
Limelight Networks, Inc. (NASDAQ: LLNW), a leading provider of digital content delivery, video, cloud security, and edge computing services, empowers customers to provide exceptional digital experiences. Limelight’s edge services platform includes a unique combination of global private infrastructure, intelligent software, and expert support services that enable current and future workflows. For more information, visit www.limelight.com
, follow us on Twitter
, Facebook
and LinkedIn
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200623005286/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom